FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
Executive Summary
With the ink of the reauthorized Prescription Drug User Fee Act still drying, FDA is signaling that it may be some time before the agency will consistently meet the performance goals of its user fee program
You may also be interested in...
With FDA's REMS Staff Overloaded, Final Guidance Could See Further Delays
The Risk Evaluation and Mitigation Strategy guidance, which has been under construction by FDA for more than a year, could see further delays before it is finalized
With FDA's REMS Staff Overloaded, Final Guidance Could See Further Delays
The Risk Evaluation and Mitigation Strategy guidance, which has been under construction by FDA for more than a year, could see further delays before it is finalized
PhRMA Wants FDA To Explain When Decisions Depart From Committee Votes
FDA should explain the why of its important regulatory decisions in consumer-friendly language, according to the Pharmaceutical Research and Manufacturers of America